Evotec and Aspireo Enter into Strategic Advisory Agreement
News Oct 03, 2012
Evotec AG and Aspireo Pharmaceuticals Limited have announced that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo’s Somatoprim.
Somatoprim (DG3173) is a new molecular entity somatostatin analogue with a unique, potentially best-in-class, pharmacological profile currently in phase I of clinical development.
Somatostatin analogues have been approved for the treatment of Acromegaly, carcinoid tumours, and Cushing’s disease but also have demonstrated significant potential in Diabetic Retinopathy.
Somatostatin analogues are generating more than USD 1.5 billion in annual sales in a continually growing market.
Under the terms of the agreement, Evotec will provide Aspireo with strategic and operational advice on the partnering of Somatoprim. In addition, Evotec will consult Aspireo on matters of clinical and pre-clinical development.
In return for such services, Evotec will retain advisory fees as well as participate in the economic success of Somatoprim.
Dr Werner Lanthaler, CEO of Evotec, commented: “This agreement marks a new business model for asset centric biotech companies who want to combine capital efficiency with access to high quality and often very specialized pre-clinical, clinical, regulatory and commercial expertise. Aspireo is a pioneer in pursuing a model of extreme capital efficiency while not compromising on quality and speed. We are excited to advise and support Aspireo in its partnering efforts for Somatoprim.”
Carsten Dehning, CEO of Aspireo, added: “Aspireo is combining the strengths of a project focused company with the benefits of accessing complete teams with leading expertise drug development and proven partnering skills. This strategic advisory agreement comes at a time when we are getting closer to reaching clinical proof of concept for Somatoprim. Evotec’s reach into the pharmaceutical industry, combined with its own experience in clinical development and partnering of clinical stage assets, makes it the partner of choice for Aspireo.”
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018